Ingersoll Rand Inc.

source: coverage-next-full ticker: IR step: "01" title: Business Overview — Ingersoll Rand Inc. created: 2026-05-29

Step 01 — Business Overview

Company Identity

Ingersoll Rand Inc. is a global provider of mission-critical flow creation and industrial technologies. The company was created in February 2020 when Gardner Denver Holdings merged with the Industrial segment of Ingersoll-Rand plc (the climate/HVAC assets were spun off as Trane Technologies). The combined entity retained the iconic "Ingersoll Rand" brand given its 150-year industrial heritage and customer recognition.

CEO Vicente Reynal, who led Gardner Denver's highly successful private equity-to-public transformation under KKR, has continued the same operating philosophy at IR — disciplined M&A integration via the IRX operating model, aggressive margin improvement, and compounding through bolt-on acquisitions.

Operating Segments

Industrial Technologies & Services (ITS) — ~77% of Revenue

ITS is the core legacy Gardner Denver business. It manufactures and services compressed air systems, gas compression equipment, blowers, and vacuum systems. Products include:

• Compressed Air Systems: Rotary screw, reciprocating, and centrifugal compressors under brands including Ingersoll Rand, CompAir, Elmo Rietschle, Gardner Denver, and Tamrotor.
• Blowers & Vacuum Systems: Positive displacement blowers, rotary vane, and dry-screw vacuum pumps.
• Power Tools & Assembly Tools: Pneumatic and electric tools under Ingersoll Rand, Chicago Pneumatic, and Desoutter brands; heavy-duty industrial fastening systems.
• Aftermarket Services: A critical component — ~35-40% of ITS revenue comes from parts, service, and consumables. This recurring revenue stream generates significantly higher margins than new equipment.

ITS End Markets: General manufacturing, chemicals, food & beverage, energy, automotive, semiconductor, and infrastructure.

ITS Adjusted EBITDA Margin: ~26-28% (FY2024 est.), reflecting high aftermarket mix and lean IRX execution.

Precision & Science Technologies (PST) — ~23% of Revenue

PST was built largely through acquisition, anchored by ILC Dover (acquired 2021) and Seepex (acquired 2022). It serves more specialized, higher-growth end markets:

• Life Sciences & Medical: Flexible containment solutions (ILC Dover), specialty diaphragm pumps, peristaltic pumps for pharmaceutical manufacturing, bioprocessing, and drug delivery.
• Specialty Pumps: Seepex progressive cavity pumps (food, wastewater, energy), ARO fluid management, and Milton Roy dosing/metering pumps.
• Industrial Air: Specialty compressed air for food/beverage, electronics, and clean-room environments.

PST End Markets: Pharmaceutical, bioprocessing, medical devices, wastewater treatment, food & beverage, semiconductor.

PST Adjusted EBITDA Margin: ~26-28% (FY2024 est.), premium to ITS given specialty mix.

Geographic Mix

International exposure (~55%) provides diversification but creates FX translation headwinds/tailwinds. IR actively hedges transactional FX risk but not translation risk.

Business Model Characteristics

Revenue Model:

• New equipment/capital sales (~60%)
• Aftermarket parts, service contracts, consumables (~40%)

The aftermarket revenue mix is a structural advantage — it is:

1. Higher margin than OEM equipment
2. Recurring and contractual in nature
3. Sticky (customers prefer OEM parts/service for warranty/safety)
4. Less cyclical than new equipment capex

Pricing Power: IR has demonstrated consistent pricing above inflation. The company achieved 3-5% annual price realization in FY2022-2024, offsetting raw material inflation and driving margin expansion.

The IRX Operating System

IRX (Ingersoll Rand Excellence) is a proprietary continuous improvement framework modeled on Danaher Business System principles. It encompasses:

• Lean manufacturing and waste elimination
• 80/20 analysis for portfolio simplification
• Value-based pricing discipline
• M&A integration playbook — standardized 100-day integration process

IRX is the primary mechanism through which IR extracts margin improvement from acquisitions (typically 400-600 bps of margin expansion within 3 years). This system is central to the IR investment thesis.

Brand Portfolio

Key brands: Ingersoll Rand, Gardner Denver, CompAir, ARO, Milton Roy, Seepex, ILC Dover, Thomas, NASH, Robuschi, Elmo Rietschle, Chicago Pneumatic, Desoutter.

Competitive Positioning

IR occupies #1 or #2 market position in compressed air/vacuum systems and specialty pumps globally. The company competes with Atlas Copco (dominant in compressors), Parker Hannifin (diversified motion/control), SPX FLOW, and a long tail of regional specialists.

source: coverage-next-full ticker: IR step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29

Step 04 — Financial Snapshot

3-Year Income Statement Summary

Note: "Adjusted" figures exclude purchase accounting amortization (~$250-280M/year), restructuring charges, M&A transaction costs, and other non-recurring items. The large D&A relative to EBIT reflects substantial intangible amortization from the Gardner Denver + Ingersoll-Rand Industrial merger and subsequent acquisitions.

Margin Bridge Analysis

Gross Margin Expansion (40.8% → 43.0%): Driven by:

1. Pricing actions (3-5% annually) outpacing material cost inflation
2. Mix shift toward aftermarket/service (higher margin) and PST specialty products
3. IRX lean manufacturing driving COGS reduction
4. Supply chain normalization post-COVID (freight, semiconductors, steel)

EBITDA Margin Expansion (22.2% → 24.6%): Driven by:

1. Gross margin flow-through
2. SG&A leverage on higher revenue base
3. IRX-driven operating efficiency in acquired businesses
4. Partially offset by continued integration investments

Target EBITDA Margin: Management has guided to ~28-30% Adj. EBITDA margin by FY2027, implying continued 150-200 bps of annual margin expansion — ambitious but supported by ITS operational leverage and PST margin normalization post-ILC Dover integration.

Key Profitability Metrics

GAAP vs. Adjusted Reconciliation Notes

The large gap between GAAP EPS ($1.68) and Adjusted EPS ($3.09) in FY2024 primarily reflects:

1. Purchase Accounting Amortization: ~$260M annually from intangible assets created by the 2020 merger and subsequent acquisitions. This is non-cash and will decline over time as intangibles are fully amortized.
2. Restructuring: ~$40-60M annually as IR integrates acquisitions and optimizes its manufacturing footprint.
3. M&A Transaction Costs: Episodic deal costs (~$20-40M annually).

Investors should watch amortization carefully — it is projected to decline ~$20-30M annually through 2028, providing an EPS tailwind even at constant operating performance.

Free Cash Flow

The step-up in FCF from FY2022 to FY2023 partly reflects normalization of working capital after the 2021-2022 supply chain disruption (IR built inventory buffers that were subsequently released). Ongoing FCF generation is expected to be ~$1B+ annually, providing significant capital allocation optionality.

Balance Sheet Summary

The leverage profile has been declining steadily from the peak post-ILC Dover acquisition (~3.5x in 2021). Management targets ~2.0x net leverage as the steady-state level, which permits continued bolt-on M&A while maintaining investment-grade credit.

Valuation Context

At a share price of approximately $70-75 (mid-2025 estimate), IR trades at:

• ~16-18x NTM Adjusted EPS
• ~13-15x NTM Adjusted EBITDA
• ~16-18x NTM FCF

These multiples represent a discount to Atlas Copco (20-25x EV/EBITDA) but a premium to broader U.S. industrials (12-14x EV/EBITDA), reflecting IR's premium-quality business model, compounding M&A strategy, and margin expansion runway.

source: coverage-next-full ticker: IR step: "12" title: Catalysts — Near-Term & Long-Term created: 2026-05-29

Step 12 — Catalysts

Near-Term Catalysts (0-12 months)

1. ILC Dover / PST Revenue Recovery

The single most anticipated near-term catalyst. After 2+ years of destocking in single-use bioprocessing, pharma customers are expected to normalize procurement in 2025. IRB/management commentary pointing to order recovery in PST would be a positive re-rating catalyst. A return to 6-8% PST organic growth vs. the recent 2-4% would add ~$100M of revenue at high margin.

2. CHIPS Act Semiconductor Fab Orders

US semiconductor fab construction (Intel Ohio, TSMC Arizona, Samsung Texas, Micron) is progressing. IR's oil-free compressors, vacuum systems, and ultrapure water tools are required for cleanroom environments. Large individual fab orders can be $30-60M each. Tangible order wins or management commentary on the semiconductor pipeline are upside catalysts.

3. European Industrial Recovery

German industrial production and broader Euro-area PMI recovery would be a meaningful positive. ITS EMEA organic growth recovery from ~0% to 3-5% would add ~$60-80M in high-incremental-margin revenue. ECB rate cuts and energy cost normalization support this.

4. Accretive Bolt-On Acquisition Announcement

IR typically announces 2-4 bolt-on acquisitions per quarter. A well-priced acquisition in specialty pumps, digital services, or life sciences would reinforce the M&A compounding narrative. Markets react positively to well-executed, in-strategy bolt-ons.

5. Margin Guidance Increase

If EBITDA margin continues to track above guidance (management targets ~28-30% by FY2027), an upward margin guidance revision at any quarterly earnings would drive consensus EPS upgrades and multiple expansion.

Long-Term Catalysts (1-5 years)

1. EBITDA Margin Convergence to 28-30%

IR management has set a long-term target of 28-30% Adj. EBITDA margin vs. ~24.6% today. The path involves continued IRX margin improvement across ITS and PST, further aftermarket mix shift, and digital revenue growth. Achieving this margin target would:

• Increase EBITDA by ~$250-400M annually at current revenue
• Drive significant EPS accretion
• Support multiple re-rating toward Atlas Copco levels (currently at a 5-7x EV/EBITDA discount)

2. Atlas Copco Multiple Convergence

Atlas Copco trades at ~20-25x EV/EBITDA; IR trades at ~14-16x. The multiple gap reflects:

• Atlas Copco's longer track record and higher ROIC
• Atlas Copco's superior geographic scale in EMEA/Asia
• Investor perception of IR as a "newer" quality compounder

As IR's track record lengthens and ROIC improves, the multiple gap should compress. Even a 2-3 turn EV/EBITDA expansion would translate to 15-25% stock upside above fundamental growth.

3. Life Sciences Market Secular Growth

The ILC Dover and PST life sciences franchise is exposed to the structural growth of biologic drug manufacturing, cell and gene therapy, and GLP-1 drug production. These represent multi-year secular growth drivers independent of cyclical factors.

4. Energy Transition / Industrial Decarbonization

IR's energy-efficient compressors, electrification-compatible tools, and hydrogen compression capabilities position it favorably in the industrial decarbonization trend. Regulatory tailwinds (EU industrial efficiency mandates, DOE standards) should sustain replacement demand well into the 2030s.

5. Emerging Market Infrastructure Growth

Asia-Pacific and Latin America manufacturing investment is a multi-decade growth driver. IR is investing in local manufacturing and service network expansion in India, Southeast Asia, and Mexico — markets expected to grow at 8-12% annually.

Negative Catalysts to Monitor

• Prolonged European industrial recession
• ILC Dover recovery further delayed into 2026+
• Large ($3B+) dilutive acquisition that lever-up the balance sheet
• CEO Reynal departure
• China trade policy escalation impacting IR's Chinese manufacturing operations

Bull Case

• IRX margin execution accelerates to 28%+ EBITDA margin by FY2026 (vs. consensus ~25-26%), driving Adjusted EPS of $4.00+ vs. consensus $3.50; combined with modest multiple re-rating toward Atlas Copco, stock could reach $100+ representing 30-40% upside.
• ILC Dover / PST recovery in H1 2025 exceeds expectations, with organic growth re-accelerating to 8-10%, validating the $2.65B acquisition thesis and demonstrating IR's IRX capability in life sciences; this would be a transformational confidence catalyst.
• Three-year M&A compounding adds $500M+ of EBITDA as IR deploys $1.5B+ across 15-20 bolt-on acquisitions with consistent IRX execution, driving EPS to $4.50-5.00 by FY2028 and making IR a 3x EBITDA compounder since formation.

Bear Case

• ILC Dover proves to be a value-destroying acquisition — life sciences market remains depressed for 3+ years, ILC Dover EBITDA plateaus at $250M vs. the $400M+ target, goodwill impairment recognized, and PST margins stall below 25%; investor confidence in IR's M&A discipline damaged, multiple re-rates to 12x EV/EBITDA.
• European industrial recession deepens and persists through 2026, causing ITS EMEA organic growth to decline 5-8%, compressing group organic growth to near zero; combined with a global industrial capex downturn, IR misses FY2025 guidance and re-rates to a low-teens EV/EBITDA multiple (stock -25%).
• CEO Vicente Reynal departs (retirement, health, competing opportunity), removing the key architect of the IRX strategy and M&A compounding story; the resulting key-man discount, uncertainty about the M&A pipeline, and potential strategy pivot cause a 15-20% de-rating.